RENBP and acute myeloid leukemia: Autologous TILs based therapies could be a novel therapeutic strategy for AML if we can (1) phenotypically identify TILs, (2) expand TILs ex vivo to sufficient numbers for clinical use, (3) demonstrate cytotoxic effect to autologous AML blasts and (4) bioengineer TILs to restore their Ag-specific cytotoxic functions.